OncoHost Named Gold Winner in 2025 Merit Awards for Business in Research & Development

BINYAMINA, Israel and CARY, N.C., July 9, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has been named a Gold Winner in the 2025 Merit Awards for Business in the Research and Development category.

Presented annually by the Merit Awards, this program celebrates the world's most innovative companies and individuals driving measurable progress across industries. OncoHost was selected for its groundbreaking R&D work powering the PROphet^® platform - an AI-driven proteomics solution that analyzes the patient's plasma proteome using bioinformatics and machine learning to deliver both predictive power and biological explainability.

"Earning the Gold in Research & Development from the Merit Awards is a meaningful validation of the bold scientific work being done at OncoHost," said Ofer Sharon, MD, CEO of OncoHost. "This recognition reinforces our mission to empower oncologists with a predictive compass, ensuring each patient has the best chance at the right treatment."

OncoHost's R&D framework brings together machine learning, proteomics, systems biology, and translational medicine. Its multidisciplinary team, including theoretical physicists, molecular biologists, algorithm developers, and clinicians—works collaboratively to investigate mechanisms of treatment resistance and support the expansion of new clinical indications.

The company's flagship product, PROphetNSCLC^™, is the first AI-powered liquid biopsy proteomics test developed to guide first-line immunotherapy decisions in metastatic non-small cell lung cancer (NSCLC). Following its success, PROphetRCC^™ (renal cell carcinoma) and PROphetMELANOMA^™ are currently in advanced clinical development and have entered the launch phase.

Beyond immunotherapy response prediction, OncoHost is broadening the platform's clinical utility with the development of PROphetirAE^™, a tool designed to identify patients at risk of severe immune-related adverse events before treatment begins. Together, OncoHost's solutions support a more personalized and proactive approach to care - aligning the right treatment to the patient while helping to reduce avoidable risk.

This award reflects OncoHost's continued progress in advancing precision oncology. With a growing clinical pipeline, strong IP portfolio, and expanding presence in peer-reviewed literature, the company remains focused on developing biomarker-driven tools to support more informed cancer care.

About OncoHost

OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina, transforming the approach to precision medicine for improved patient outcomes. OncoHost's proprietary platform, PROphet^®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC^™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival.

Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, Facebook, and YouTube.

About the Merit Awards 
The Merit Awards recognize the best in industry across leadership, innovation, and impact. Designed to spotlight organizations and individuals making a measurable difference, the program highlights those redefining their sectors through ingenuity, excellence, and transformative thinking. For more information, visit www.merit-awards.com.

Media Contact:
Mimi Strahl – Ben Simon
Senior Marcom Associate
[email protected]
+972-50-428-1138

Photo: https://mma.prnewswire.com/media/2726810/OncoHost_Merit_Awards.jpg

SOURCE OncoHost